Cygnus Technologies, a Maravai LifeSciences company, announced today that it has achieved ISO 9001:2015 certification. This designation certifies a high level of quality assurance and consistency and will be particularly important to Cygnus Technologies customers engaged in biotherapeutics manufacturing.
ISO is the International Organization for Standardization, and certification is a demonstration of Cygnus Technologies’ commitment to continuously deliver high-quality products. ISO standards help guide manufacturing and quality-control processes, documentation systems, customer service, product design and distribution and other support functions.
“Cygnus Technologies has always had a strong quality mindset, as our customers demand it,” said Christine Dolan, Cygnus chief operating officer. “Utilizing the ISO 2015-9001 standard to continually improve our quality management system made a lot of sense for our operations. It gives us an internationally recognizable foundation for growth.”
“Following the ISO framework helps us improve productivity, enhance customer satisfaction and ensure business continuity,” said Ericka Crawford, vice president of quality for Maravai LifeSciences. “It’s a win for us and a win for our customers.”
About Cygnus Technologies
Cygnus Technologies develops, manufactures and markets assay kits and related services that enable pharmaceutical and biotech companies to detect and identify host cell impurities in biotherapeutics, an important step in regulatory approval and quality control processes. With products, services and expert advice, Cygnus helps biopharmaceutical companies quickly move new therapeutics through the development and approval stages to market. With headquarters in Southport, N.C., Cygnus Technologies serves customers worldwide through a global network. A privately held company, Cygnus Technologies was acquired by Maravai LifeSciences in 2016.
Contacts for the media:
David Weber, Chief Commercial Officer